OT1-02-03: EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) in Combination with Lapatinib (L), Trastuzumab (T) or Both for the Treatment of Hormone Receptor-Positive (HR+), HER2+ Metastatic Breast Cancer (MBC).

Aromatase Inhibitor ◽

Hormone Receptor ◽

Metastatic Breast ◽

Safety And Efficacy ◽

PD01-01: Randomized Phase II Trial of Fulvestrant with or without Dasatinib in Postmenopausal Patients with Hormone Receptor-Positive Metastatic Breast Cancer Previously Treated with an Aromatase Inhibitor.

10.1158/0008-5472.sabcs11-pd01-01 ◽

2011 ◽

Cited By ~ 6

Author(s):

GL Wright ◽

J Blum ◽

LK Krekow ◽

KJ McIntyre ◽

ST Wilks ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Randomized Phase Ii ◽

Previously Treated

Abstract CT330: Phase I study of PI3Kα inhibitor BYL719 + aromatase inhibitor (AI) in patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

10.1158/1538-7445.am2015-ct330 ◽

2015 ◽

Cited By ~ 3

Author(s):

Payal D. Shah ◽

Mary E. Moynahan ◽

Shanu Modi ◽

Nicola Hamilton ◽

Betty Ann Caravella ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Phase I Study ◽

Metastatic Breast ◽

Abstract OT1-03-06: Phase IB/II clinical trial to evaluate safety and efficacy of tucatinib in combination with palbociclib and letrozole in patients with hormone receptor positive and HER2-positive metastatic breast cancer

10.1158/1538-7445.sabcs17-ot1-03-06 ◽

2018 ◽

Cited By ~ 1

Author(s):

E Shagisultanova ◽

J Diamond ◽

A Stopeck ◽

L Pusztai ◽

R O'Regan ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Hormone Receptor ◽

Metastatic Breast ◽

Her2 Positive ◽

Safety And Efficacy ◽

Phase Ib ◽

A luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer

Surgery Today ◽

10.1007/s00595-013-0765-4 ◽

2013 ◽

Vol 44 (9) ◽

pp. 1678-1684 ◽

Cited By ~ 4

Author(s):

Kimihiro Tanaka ◽

Eriko Tokunaga ◽

Nami Yamashita ◽

Kenji Taketani ◽

Sayuri Akiyoshi ◽

...

Keyword(s):

Breast Cancer ◽

Luteinizing Hormone ◽

Aromatase Inhibitor ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Metastatic Breast ◽

Second Line ◽

Luteinizing Hormone Releasing Hormone ◽

Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-010-1226-z ◽

2010 ◽

Vol 125 (1) ◽

pp. 137-143 ◽

Cited By ~ 24

Author(s):

Claudine Isaacs ◽

Pia Herbolsheimer ◽

Minetta C. Liu ◽

Mary Wilkinson ◽

Yvonne Ottaviano ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Metastatic Breast ◽

Abstract PS12-02: Safety and efficacy of an alternative schedule of palbociclib (PAL) in hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) and the utility of serum thymidine kinase 1 (sTK1) activity in predicting PAL response

10.1158/1538-7445.sabcs20-ps12-02 ◽

2021 ◽

Author(s):

Jairam Krishnamurthy ◽

Jingqin Luo ◽

Rama Suresh ◽

Foluso Ademuyiwa ◽

Caron Rigden ◽

...

Keyword(s):

Breast Cancer ◽

Thymidine Kinase ◽

Hormone Receptor ◽

Metastatic Breast ◽

Thymidine Kinase 1 ◽

Safety And Efficacy ◽

Hormone Receptor Positive ◽

Alternative Schedule ◽

Serum Thymidine Kinase 1

Abstract S3-07: Letrozole plus dasatinib improves progression-free survival (PFS) in hormone receptor-positive, HER2-negative postmenopausal metastatic breast cancer (MBC) patients receiving first-line aromatase inhibitor (AI) therapy

10.1158/0008-5472.sabcs13-s3-07 ◽

2013 ◽

Cited By ~ 6

Author(s):

D Paul ◽

SJ Vukelja ◽

FA Holmes ◽

J Blum ◽

KJ McIntyre ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Metastatic Breast ◽

Progression Free Survival ◽

First Line ◽

Free Survival ◽

Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs14-pd5-3 ◽

2015 ◽

Cited By ~ 1

Author(s):

Payal D Shah ◽

Mary Ellen Moynahan ◽

Shanu Modi ◽

Betty Ann Caravella ◽

Farrah M Datko ◽

...

Keyword(s):

Breast Cancer ◽

Phase I ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Phase I Trial ◽

Metastatic Breast ◽

High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: A confirmatory prospective study

Cancer ◽

10.1002/cncr.23043 ◽

2007 ◽

Vol 110 (10) ◽

pp. 2178-2185 ◽

Cited By ~ 7

Author(s):

Ramon Colomer ◽

Antonio Llombart-Cussac ◽

Belen Lloveras ◽

Manuel Ramos ◽

Jose I. Mayordomo ◽

...

Keyword(s):

Breast Cancer ◽

Prospective Study ◽

Aromatase Inhibitor ◽

Hormone Receptor ◽

Metastatic Breast ◽

Extracellular Domain ◽

Abstract P3-11-02: A randomized phase II trial of toremifene (120 mg) versus fulvestrant (500 mg) after prior non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer (Hi-FAIR fx study)

10.1158/1538-7445.sabcs17-p3-11-02 ◽

2018 ◽

Author(s):

R Nishimura ◽

Y Yamamoto ◽

K Narui ◽

Y Kijima ◽

Y Hozumi ◽

...

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitor ◽

Postmenopausal Women ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Hormone Receptor Positive ◽

Randomized Phase Ii